Potential antithrombotic and fibrinolytic properties of the angiotensin converting enzyme inhibitors

Journal of Thrombosis and Thrombolysis

Volumn 1, Issue 3, 1995, Pages 251-257

  Ridker, Paul M ^a,b   Vaughan, Douglas E ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

angiotensin; fibrinolysis; myocardial infarction; plasminogen activator inhibitor; tissue type plasminogen activator

Indexed keywords

EID: 0001719230     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/BF01060734     Document Type: Article

References (53)

1. History of the design of captopril and related inhibitors of angiotensin converting enzyme
2. Converting-enzyme inhibitors in the treatment of hypertension
3. ACE inhibitors: A cornerstone of the treatment of heart failure
4. Angiotensin-converting enzyme inhibition in congestive heart failure: Benefit and perspective
5. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II: Evidence of a potential interaction between the renin angiotensin system and fibrinolytic function
6. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction
7. Effect of Enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
8. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction
9. Ventricular remodeling after myocardial infarction: Experimental observations and clinical implications
10. Effects of enalapril on mortality in severe congestive heart failure
11. Blood pressure, stroke, and coronary heart disease II, short-term reductions in blood pressure: Overview of randomized drug trials in their epidemiological context
12. Essential hypertension: Renin and aldosterone, heart attack and stroke
13. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension
14. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions
15. Plasma renin activity and ischemic heart disease
16. Effects of captopril on ischemia and dysfunction of the left ventricle after myocardial infarction
17. Trandolapril inhibits atherosclerosis in the Watanabe heritable hyperlipidemic rabbit
18. Angiotensin II-stimulated protein synthesis in cultured vascular smooth muscle cells
19. Angiotensin-II: Hemodynamic regulator or growth factor?
20. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall
21. Angiotensin II stimulates collagen synthesis in cultured vascular smooth muscles
22. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury
23. Plasma angiotensinconverting enzyme activity and carotid wall thickening
24. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: A multicenter, randomized, double-blind placebo-controlled trial
25. Coronary vasodilatation and improved myocardial lactate metabolism after angiotensin converting enzyme inhibition with enalapril in patients with congestive heart failure
26. Plasminogen activator inhibitors
27. Endogenous tissue-type plasminogen activator and risk of myocardial infarction
28. Prospective study of endogenous tissue plasminogen activator and risk of stroke
29. Baseline fibrinolytic state and the risk of future venous thrombosis. A prospective study of endogenous tissue-type plasminogen activator and plasminogen activator inhibitor
30. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction
31. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction
32. Plasminogen activator and plasminogen activator inhibitor activities in men with coronary artery disease
33. Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease
34. Plasminogen activator inhibitor in the blood of patients with coronary artery disease
35. Inhibition of plasminogen activator inhibitor-1 activity results in premotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis
36. Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator ihibitor
37. Brief report: Complete deficiency of plasminogen-activator inhibitor type 1 due to a frame shift mutation
38. Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene
39. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study
40. The use of ACE-inhibitors in hypertension
41. Angiotensin II induces plasminogen activator inhibitor (PAI-1) in vitro (abstract)
42. Angiotensin II induces secretion of plasminogen activator inhibitor-1 and a tissue metalloprotease inhibitor-related protein from rat brain astrocytes
43. The plasminogen activator and coagulation factor VIII responses to adrenaline, noradrenaline, and salbutamol in man
44. In vitro stimulation of plasminogen activator release from vein walls by adrenaline
45. Fibrinolytic response during exercise and epinephrine infusion in the same subjects
46. Influence of metoprolol treatment on sympatho-adrenal activation of fibrinolysis
47. Effects of captopril therapy on endogenous fibrinoysis in men with recent, uncomplicated myocardial infarction
48. Effect of Angiotensin II on collagen induced platelet aggregation in normotensive subjects
49. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction
50. Deletion polymorphism in angiotensin-converting enzyme gene associated with parental history of myocardial infarction
51. An insertion/deletion polymorphism in the angiotensin-1 converting enzyme gene accounting for half the variance of serum enzyme levels
52. Angiotensin-converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden cardiac death
53. Angiotensinconverting enzyme DD genotype in patients with ischaemic or idiopathic dilated cardiomyopathy